Trastuzumab Deruxtecan (T-DXd): Tailoring Treatment and Companion Diagnostics (CDx) by Liquid Biopsy
Condition: Metastatic Breast Cancer Intervention: Diagnostic Test: HER2-D is the use of a non-invasive liquid biopsy method to non-invasively and objectively assess HER2 status at recruitment Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials